JP Morgan Chase
LBPH

JP Morgan Chase’s Longboard Pharmaceuticals, Inc. Common Stock LBPH Stock Holding History

JP Morgan Chase’s Portfolio LBPH Stock Details LBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-97,995
Closed -$3.27M – 7908
2024
Q3 		$3.27M Sell
97,995
-508,600
-84% -$17.5M ﹤0.01% 3563
2024
Q2 		$16.4M Buy
606,595
+101,421
+20% +$2M ﹤0.01% 2017
2024
Q1 		$10.9M Sell
505,174
-29,542
-6% -$644K ﹤0.01% 2398
2023
Q4 		$3.22M Buy
534,716
+1,214
+0.2% +$6.05K ﹤0.01% 3458
2023
Q3 		$2.97M Sell
533,502
-33,803
-6% -$218K ﹤0.01% 3243
2023
Q2 		$4.16M Buy
+567,305
New +$4.29M ﹤0.01% 3018

JP Morgan Chase's LBPH Position: Q4 2024 in Review

JP Morgan Chase sold out of Longboard Pharmaceuticals, Inc. Common Stock (LBPH) in Q4 2024, closing a stake of 97,995 shares — an estimated $3.27M sold.

JP Morgan Chase first reported a position in LBPH in Q2 2023 and held it in 6 quarters. The position peaked at $16.4M in Q2 2024. 0 funds tracked by Wall St. Rank hold LBPH as of Q4 2024.

  • JP Morgan Chase reported no remaining Longboard Pharmaceuticals, Inc. Common Stock position as of Q4 2024 after selling out during the quarter.
  • JP Morgan Chase sold 97,995 Longboard Pharmaceuticals, Inc. Common Stock shares in Q4 2024, an estimated $3.27M.
  • JP Morgan Chase first reported a position in Longboard Pharmaceuticals, Inc. Common Stock in Q2 2023 and held it in 6 quarters.
  • JP Morgan Chase's Longboard Pharmaceuticals, Inc. Common Stock position peaked at $16.4M in Q2 2024.
  • 0 funds tracked by Wall St. Rank held Longboard Pharmaceuticals, Inc. Common Stock as of Q4 2024.

Based on JP Morgan Chase's 13F filing for Q4 2024, filed 12 Feb 2025.